Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Medtronic says it plans use data from a study of biventricular pacing of the heart’s 2 lower chambers to back an expaned indication for its cardiac rhythm therapy devices. Medtronic (NYSE:MDT) plans to use new study results to ask the FDA to expand the indication for its cardiac resynchronization therapy devices, to include patients with atrioventricular block and left ventricular systolic dysfunction. A recent study published in the New England Journal of Medicine showed that simultaneously pacing the lower chambers of the heart with a CRT device significantly improves heart failure symptoms and quality of life in some patients with heart disease. “Biventricular pacing was superior to conventional right ventricular pacing in patients with atrioventricular block and left ventricular systolic dysfunction with NYHA class I, II, or III heart failure,” the study’s authors conclude in the April 25 edition of NEJM.
Help employers find you! Check out all the jobs and post your resume.
